Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.57 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | GBA1 | P04062 | 1/20 | 0.44 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2016258 | 1.00 | LTA4H (0.57) | LTA4HSIGMAR1ALDH1A1LMNAPOLB | |
| SCHEMBL2016261 | 1.00 | LTA4H (0.57) | LTA4HSIGMAR1ALDH1A1LMNAPOLB | |
| SCHEMBL16439718 | 0.92 | LTA4H (0.55) | LTA4HSIGMAR1ALDH1A1LMNAGBA1 | |
| SCHEMBL19878947 | 0.92 | ALDH1A1 (0.51) | LTA4HSIGMAR1ALDH1A1LMNAPOLB | |
| SCHEMBL14033540 | 0.92 | LTA4H (0.55) | LTA4HSIGMAR1ALDH1A1LMNAGBA1 | |
| SCHEMBL19878948 | 0.92 | ALDH1A1 (0.51) | LTA4HSIGMAR1ALDH1A1LMNAPOLB | |
| SCHEMBL2062715 | 0.88 | LTA4H (0.60) | LTA4HSIGMAR1ALDH1A1GBA1FUCA1 | |
| SCHEMBL28142979 | 0.88 | LTA4H (0.60) | LTA4HSIGMAR1ALDH1A1GBA1FUCA1 | |
| SCHEMBL692066 | 0.88 | LTA4H (0.60) | LTA4HSIGMAR1ALDH1A1GBA1FUCA1 | |
| SCHEMBL3495379 | 0.87 | LTA4H (0.59) | LTA4HSIGMAR1ALDH1A1CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119775260-A | Pyrimidine-2, 4 (1H, 3H) -dione compounds, preparation method, pharmaceutical composition and application thereof | 中国医学科学院药物研究所 | 2025-04-08 | — | — | CN | disclosed |
| US-20230165865-A1 | HETEROARYLDIHYDROPYRIMIDINE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-01 | — | — | US | disclosed |
| US-20230165865-A1 | HETEROARYLDIHYDROPYRIMIDINE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-01 | — | — | US | disclosed |
| US-20230165865-A1 | HETEROARYLDIHYDROPYRIMIDINE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-01 | — | — | US | disclosed |
| EP-3636651-A1 | HEXAHYDROPYRAZINOBENZ- OR -PYRIDO-OXAZEPINES CARRYING AN OXYGEN-CONTAINING SUBSTITUENT AND USE THEREOF IN THE TREATMENT OF 5-HT2C-DEPENDENT DISORDERS | AbbVie Deutschland GmbH & Co. KG (DE) | 2020-04-15 | — | — | EP | disclosed |
| US-20180339996-A1 | HEXAHYDROPYRAZINOBENZ- OR -PYRIDO-OXAZEPINES CARRYING AN OXYGEN-CONTAINING SUBSTITUENT AND USE THEREOF IN THE TREATMENT OF 5-HT2C-DEPENDENT DISORDERS | AbbVie Deutschland GmbH & Co. KG (DE) | 2018-11-29 | — | — | US | disclosed |
| EP-3380483-A1 | HEXAHYDROPYRAZINOBENZ- OR -PYRIDO-OXAZEPINES CARRYING AN OXYGEN-CONTAINING SUBSTITUENT AND USE THEREOF IN THE TREATMENT OF 5-HT2C-DEPENDENT DISORDERS | Abbvie Deutschland GmbH & Co. KG (DE) | 2018-10-03 | — | — | EP | disclosed |
| WO-2017089458-A1 | HEXAHYDROPYRAZINOBENZ- OR -PYRIDO-OXAZEPINES CARRYING AN OXYGEN-CONTAINING SUBSTITUENT AND USE THEREOF IN THE TREATMENT OF 5-HT2C-DEPENDENT DISORDERS | AbbVie Deutschland GmbH & Co. KG (DE) | 2017-06-01 | — | — | WO | disclosed |
| EP-3150607-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | AbbVie Inc. (US) | 2017-04-05 | — | — | EP | disclosed |
| EP-2560973-B1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | ABBVIE INC (US) | 2016-11-16 | — | — | EP | disclosed |
| US-20110130382-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2011-06-02 | — | — | US | disclosed |
| US-20090227560-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-10 | — | — | US | disclosed |
| US-20090156612-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
| WO-2008139941-A1 | SUBSTITUTED IMIDAZOLE COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-11-20 | — | — | WO | disclosed |
| US-20070249588-A1 | Nicotinic Acetylcholine Receptor Ligands | ASTRAZENECA AB (SE) | 2007-10-25 | — | — | US | disclosed |
| US-20070249588-A1 | Nicotinic Acetylcholine Receptor Ligands | ASTRAZENECA AB (SE) | 2007-10-25 | — | — | US | disclosed |
| US-20070249588-A1 | Nicotinic Acetylcholine Receptor Ligands | ASTRAZENECA AB (SE) | 2007-10-25 | — | — | US | disclosed |
| CN-1918166-A | Nicotinic acetylcholine receptor ligands | ASTRAZENECA AB (SE) | 2007-02-21 | — | — | CN | disclosed |
| EP-1699801-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | AstraZeneca AB (SE) | 2006-09-13 | — | — | EP | disclosed |
| WO-2005061510-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | ASTRAZENECA AB (SE) | 2005-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180339996-A1 | HEXAHYDROPYRAZINOBENZ- OR -PYRIDO-OXAZEPINES CARRYING AN OXYGEN-CONTAINING SUBSTITUENT AND USE THEREOF IN THE TREATMENT OF 5-HT2C-DEPENDENT DISORDERS | HTR2C, HTR2A, HTR5A | LTA4H 330/4885SIGMAR1 259/4885ALDH1A1 821/4885 |
| US-20090156612-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | LTA4H 1197/4885SIGMAR1 3163/4885ALDH1A1 388/4885 |
| US-20230165865-A1 | HETEROARYLDIHYDROPYRIMIDINE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | HAVCR2, HCCS, PYGL | LTA4H 2209/4885SIGMAR1 4378/4885ALDH1A1 1615/4885 |
| US-20070249588-A1 | Nicotinic Acetylcholine Receptor Ligands | CHRNA1, CHRNB1, CHRNA2 | LTA4H 880/4885SIGMAR1 240/4885ALDH1A1 500/4885 |
| US-20110130382-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | HTR4, HTR1A, HTR1D | LTA4H 618/4885SIGMAR1 77/4885ALDH1A1 1176/4885 |
| US-20090227560-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | LTA4H 1197/4885SIGMAR1 3163/4885ALDH1A1 388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.